
Australian
ACL.AXAustralian Clinical Labs Limited Price (ACL.AX)
Stock Price
Market Cap
Fetching Data...
Enterprise Value
Fetching Data...
Volume
Fetching Data...
Shares Outstanding
199,472,019
(0.8173)%Income Statement Summary
Revenue | |
Cost of Revenue | |
Gross Profit | |
Operating Expenses | |
Operating Income | |
Other Expenses | |
Net Income |


Income Statement
Australian Clinical Labs LimitedCurrency: AUD
YEAR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | |||||||||||||||||||
Revenue |
339.77M
+0% |
376.09M
+11% |
445.89M
+19% |
487.53M
+9% |
641.31M
+32% |
989.30M
+54% |
692.10M
-30% |
689.73M
0% |
|||||||||||
Cost of Revenue | |||||||||||||||||||
Cost of Revenue | 57.68M | 265.85M | 313.89M | 402.49M | 119.59M | 207.59M | 126.08M | 442.37M | |||||||||||
Gross Profit | |||||||||||||||||||
Gross Profit |
282.09M
+0% |
110.24M
-61% |
132.00M
+20% |
85.04M
-36% |
521.73M
+513% |
781.71M
+50% |
566.02M
-28% |
247.36M
-56% |
|||||||||||
Gross Profit Ratio | (0.83%) | (0.29%) | (0.30%) | (0.17%) | (0.81%) | (0.79%) | (0.82%) | (0.36%) | |||||||||||
Operating Expenses | |||||||||||||||||||
Research and Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||
General and Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 249.69M | 314.00M | 297.39M | 312.67M | |||||||||||
Selling, General & Admin... | 251.50M | 116.15M | 139.58M | 69.51M | 249.69M | 314.00M | 297.39M | 87.19M | |||||||||||
Selling & Marketing Exp... | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -225,475,000.00 | |||||||||||
Depreciation and Amortiz... | 12.51M | 11.32M | 11.51M | 77.90M | 88.05M | 106.10M | 122.76M | 128.43M | |||||||||||
Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 3.36M | -1,073,000.00 | 10.03M | 201.83M | |||||||||||
Total Operating Expenses | 306.32M | 116.15M | 139.58M | 69.51M | 416.54M | 514.03M | 514.05M | 81.55M | |||||||||||
Cost and Exponses | 364.00M | 382.00M | 453.47M | 472.00M | 536.12M | 721.62M | 640.14M | 632.82M | |||||||||||
Operating Income | |||||||||||||||||||
Operating Income |
-20,569,000.00
+0% |
-5,909,000.00
-71% |
-7,578,000.00
+28% |
15.53M
-305% |
97.59M
+528% |
256.24M
+163% |
51.85M
-80% |
56.91M
+10% |
|||||||||||
Operating Income Ratio | (-0.06%) | (-0.02%) | (-0.02%) | (0.03%) | (0.15%) | (0.26%) | (0.07%) | (0.08%) | |||||||||||
Other Income and Exp... | |||||||||||||||||||
Interest Income | 3.38M | 47.00k | 38.00k | 38.00k | 75.00k | 45.00k | 182.00k | 501.00k | |||||||||||
Interest Expenses | 0.00 | 3.65M | 3.94M | 16.57M | 10.94M | 1.34M | 3.54M | 17.04M | |||||||||||
Total Other Income/Exp... | -58,200,000.00 | -1,732,000.00 | 2.38M | 1.17M | -35,957,000.00 | -12,777,000.00 | -3,657,000.00 | -20,539,000.00 | |||||||||||
EBITDA | |||||||||||||||||||
EBITDA | -8,058,999.00 | 5.41M | 3.93M | 116.30M | 196.67M | 372.75M | 184.93M | 169.65M | |||||||||||
EBITDA ratio | (-0.02%) | (0.01%) | (0.01%) | (0.19%) | (0.29%) | (0.37%) | (0.25%) | (0.25%) | |||||||||||
Income Before Tax | |||||||||||||||||||
Income Before Tax | -27,612,000.00 | -7,641,000.00 | -9,704,000.00 | 30.89M | 86.65M | 254.90M | 48.31M | 36.37M | |||||||||||
Income Before Tax Ratio | (-0.08%) | (-0.02%) | (-0.02%) | (0.06%) | (0.14%) | (0.26%) | (0.07%) | (0.05%) | |||||||||||
Income Tax Expense | |||||||||||||||||||
Income Tax Expense | 3.58M | 1.37M | 820.00k | -10,425,000.00 | 26.26M | 76.50M | 12.27M | 12.12M | |||||||||||
Net Income | |||||||||||||||||||
Net Income | -24,031,000.00
+0% |
-9,012,000.00
-62% |
-10,524,000.00
+17% |
41.26M
-492% |
60.37M
+46% |
178.24M
+195% |
35.90M
-80% |
23.93M
-33% |
|||||||||||
Net Income Ratio | (-0.07%) | (-0.02%) | (-0.02%) | (0.08%) | (0.09%) | (0.18%) | (0.05%) | (0.03%) | |||||||||||
Earning Per Share | |||||||||||||||||||
Basic EPS | -0.12 | -0.04 | -0.05 | 0.20 | 0.40 | 0.89 | 0.18 | 0.12 | |||||||||||
Diluted EPS | -0.12 | -0.04 | -0.05 | 0.20 | 0.40 | 0.88 | 0.18 | 0.12 | |||||||||||
Share Outstanding | |||||||||||||||||||
Basic Share Outstanding | 202.30M | 202.30M | 202.30M | 202.30M | 152.10M | 201.29M | 200.57M | 198.90M | |||||||||||
Diluted Share Outstanding | 202.30M | 202.30M | 202.30M | 202.30M | 152.10M | 201.49M | 201.12M | 199.47M |